Circadian OS is developing the first FDA approved non pharmacological circadian therapy for oncology. Based on Nobel Prize-winning research out of Rockefeller University, we develop technologies that can precisely diagnose a patient's peak immunotherapy sensitivity and correct it using state of the art phototherapy. Our product has the potential to transform how we treat patients by correcting their body clocks. In immunotherapy alone this is a $50B market per year. Future applications will focus on neurodegenerative and metabolic disorders. We have secured IP from top research institutions, assembled a diverse and experienced team and advisory board, and secured partnerships with medical institutions to test our technology in the clinic.